Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | GPX4 | P36969 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974408 | 0.91 | WDR5 (0.41) | WDR5SLC6A9CNR1GPX4CACNA2D1 | |
| SCHEMBL977114 | 0.91 | WDR5 (0.41) | WDR5SLC6A9CNR1GPX4CACNA2D1 | |
| SCHEMBL974202 | 0.91 | WDR5 (0.41) | WDR5SLC6A9CNR1FABP4GPX4 | |
| SCHEMBL975275 | 0.89 | SLC6A9 (0.39) | SLC6A9CNR1GPX4MEN1KMT2A | |
| SCHEMBL977461 | 0.89 | MEN1 (0.44) | WDR5SLC6A9MEN1GAAKMT2A | |
| SCHEMBL977821 | 0.88 | WDR5 (0.42) | WDR5SLC6A9MEN1KMT2A | |
| SCHEMBL975564 | 0.88 | WDR5 (0.39) | WDR5SLC6A9CNR1GPX4CACNA2D1 | |
| SCHEMBL977321 | 0.88 | WDR5 (0.39) | WDR5SLC6A9FABP4GPX4CACNA1G | |
| SCHEMBL976402 | 0.87 | CCKBR (0.38) | SLC6A9CNR1 | |
| SCHEMBL976400 | 0.87 | CCKBR (0.38) | SLC6A9CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | claimed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | WDR5 2893/4885SLC6A9 2158/4885CNR1 250/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | WDR5 2893/4885SLC6A9 2158/4885CNR1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.